Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01805297 · ClinicalTrials.gov registry record · Phase 2
Aflibercept Injection for Proliferative Diabetic Retinopathy
A Phase 2 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01805297: Completed Phase 2 study, sponsored by University of Oklahoma.
NCT01805297 is a Phase 2 study that has completed, run by University of Oklahoma. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01805297, a Phase 2 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
Primary Outcome
Percentage of patients who had no vitreous hemorrhage before or at week 24
Interventions
- DRUG Intravitreal Aflibercept Injection
- OTHER Standard Vitrectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
What the finished NCT01805297 record still lists
NCT01805297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Intravitreal Aflibercept Injection is the first listed.
NCT01805297 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01805297 about?
NCT01805297 is a clinical study titled "Aflibercept Injection for Proliferative Diabetic Retinopathy". To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
What is the current status of trial NCT01805297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01805297?
The interventions under investigation include: Intravitreal Aflibercept Injection (DRUG), Standard Vitrectomy (OTHER).
Who is sponsoring clinical trial NCT01805297?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01805297's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia